Back to Alzheimers Disease

NCT02245568

NCT02245568
Terminated Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You must have already completed participation in one of three specific earlier TauRx research studies (TRx-237-005, TRx-237-008, or TRx-237-015) for dementia or probable Alzheimer's disease, including a 4-week follow-up visit at the end of that study
  • Alternatively, you must have already completed participation up to Week 52 in a specific earlier TauRx study (TRx-237-007) for a condition called behavioural variant frontotemporal dementia (a type of brain condition affecting behaviour and personality)
  • If you are a woman who could become pregnant, you must be willing to use reliable contraception or practice complete abstinence throughout the study
  • You (or a legal representative acting on your behalf, if needed) must be able to read, understand, and sign a written consent form agreeing to take part
  • You must have an adult caregiver who consents to be involved, can speak the language used at the study site, spends at least 1 hour a day with you at least 3 days a week, is willing to come with you to every study visit, and can confirm you are taking the study medication as directed
  • You must be able to follow the study procedures throughout the trial

Who may not be able to join:

  • People who have a history of difficulty swallowing
  • People who are currently pregnant or breastfeeding
  • People who have significant abnormal results from lab tests, heart monitoring, or scans, or who have developed a serious illness that the lead doctor believes makes the risks of joining the trial too high
  • People who are currently in another clinical trial or plan to join one during this study
  • In Germany specifically: people who are required to live in a full-time care or assisted living facility, or whose ability to freely choose to participate may be unduly influenced (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Terminated
Phase
Phase 3
Sponsor
TauRx Therapeutics Ltd
Registry
clinicaltrials_gov
Start date
1 August 2014
Est. completion
1 May 2017

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇨🇦 Canada 🇭🇷 Croatia 🇫🇮 Finland 🇫🇷 France 🇩🇪 Germany 🇲🇾 Malaysia 🇳🇱 Netherlands 🇷🇴 Romania 🇷🇺 Russia 🇸🇬 Singapore 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

9 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of Participants With Serious or Non-serious Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov